Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diabetes Therapy to Improve BMI and Lung Function in CF
NCT00072904Phase 3Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jun 2001
- Primary completion
- Dec 2007
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of insulin aspart and repaglinide in cystic fibrosis-related diabetes (CFRD) (3 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoints: Body Mass Index at 12 months and Pulmonary Function at 12 months. Started Jun 2001; status: completed.
02
Drugs
insulin aspartrepaglinide
03
Conditions
cystic fibrosis-related diabetes (CFRD)
Beyond the preview
Go deeper on NCT00072904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072904.